Can You Get a Liver Transplant If You Are an Alcoholic?

People with alcohol-related liver disease can and do receive liver transplants, and in fact alcohol-associated liver disease has become the leading reason for liver transplantation in the United States. The old assumption that active or recently active drinkers are categorically excluded is outdated, though the path to a transplant involves meeting medical and psychosocial criteria that vary from center to center. What has changed is that the rigid six-month sobriety requirement, once treated as near-universal, is no longer the only gateway. A growing body of evidence shows that carefully selected patients with severe alcohol-related liver failure can receive transplants earlier, with survival rates comparable to or better than those transplanted for other causes of liver disease.

How Alcohol-Related Liver Disease Became the Top Transplant Indication

For decades, hepatitis C was the most common reason people needed new livers. That changed as effective antiviral treatments became widely available, while rates of heavy drinking climbed. Even during the COVID-19 pandemic, transplants for alcohol-associated liver disease rose while transplants for liver cancer declined.¹ The result is that transplant teams today evaluate more patients with alcohol-related diagnoses than any other single cause. That shift has forced the transplant community to rethink old gatekeeping rules and grapple with questions about fairness, relapse risk, and how best to support patients before and after surgery.

The Six-Month Rule and Why It Is Losing Its Grip

The most well-known barrier has historically been the “six-month rule,” which requires patients with alcohol-related liver disease to remain completely sober for at least six months before they can be evaluated for transplant listing. The rule traces back to a 1983 consensus panel. It was originally designed to give the liver time to recover on its own, since some patients with early-stage alcohol-related liver damage will stabilize if they stop drinking. Over the years, though, it morphed into something different: a proxy for predicting whether someone would stay sober after transplant, and a way to ration a scarce resource.²

The trouble is that six months of sobriety is only a modest predictor of future behavior. A review of 13 studies that used multivariate analysis found that about five identified pre-transplant abstinence as a strong predictor of post-transplant relapse, but the rest did not find it significant when other factors were accounted for.³ Longer pre-transplant sobriety does appear to help — one Japanese study found that abstinence shorter than 18 months was a significant indicator of harmful relapse risk.⁴ And another study confirmed that each additional month of abstinence before transplant lowered the odds of heavy relapse afterward.⁵ But the relationship is not clean enough to justify treating six months as a hard cutoff, especially when the patient in front of you is dying.

The biggest practical problem with the rule is that some patients cannot survive six months. Severe alcoholic hepatitis that doesn’t respond to medication carries an extremely high short-term mortality rate. Telling those patients to come back after six months of sobriety is, in many cases, telling them to go home and die. After decompensation — when the liver loses its ability to perform basic functions — progression to acute-on-chronic liver failure often means death, and when transplant is denied, palliative care becomes the only remaining option.⁶

Early Transplantation for Severe Alcoholic Hepatitis

Recognizing that the six-month rule was leaving the sickest patients to die, several transplant centers began studying early liver transplantation — listing patients who had severe alcohol-related hepatitis that didn’t respond to standard medical therapy, even without meeting a six-month sobriety window. The results have been striking. In a landmark prospective study, patients who received early transplants had significantly higher survival at both six and 24 months compared to matched patients who were denied transplant: roughly 77% versus 23% alive at six months, and 71% versus 23% at two years.⁷ Another multi-center U.S. study found that cumulative survival after early transplant was about 94% at one year and 84% at three years.⁸

The survival numbers for early transplant recipients are not just acceptable — they compare favorably to outcomes for patients transplanted for other liver diseases. One recent study found that post-transplant survival was similar between early-transplant and standard-listing alcohol-related liver disease patients, and actually superior to that of patients transplanted for non-alcohol-related causes.⁹ These findings have reshaped the debate. By 2023, about two-thirds of transplant center directors surveyed said their center had established criteria for listing candidates with severe alcohol-related liver disease for early transplant.¹⁰

What the Evaluation Actually Looks Like

Getting listed for a liver transplant with an alcohol-related diagnosis involves more than just proving you are sober. Transplant teams conduct a psychosocial evaluation designed to assess how likely you are to stay engaged with treatment after surgery. Several standardized tools exist for this purpose, and in studies comparing patients who were accepted for early transplant against those who were not, the accepted patients consistently scored in a direction suggesting stronger social support, fewer psychiatric risk factors, and greater motivation for sobriety.¹¹

The criteria that centers weigh most heavily include predicted patient survival, predicted graft survival, and having a low risk of relapse — with over half of surveyed directors flagging patient survival and low relapse risk as their top considerations.¹⁰ In practical terms, the team wants to know whether you have a support system, whether you acknowledge your alcohol use disorder, whether you have untreated psychiatric conditions, and whether you are willing to engage with addiction treatment. The specific scoring tools vary from center to center, and there is no single national standard for which psychosocial instrument a program must use.

Post-Transplant Relapse and What It Means

One of the biggest concerns — both medically and in public perception — is that transplant recipients with alcohol-related disease will drink again after receiving a new liver. The honest answer is that a meaningful number do. In one study of 67 transplant recipients followed for a median of about three and a half years, roughly 27% experienced alcohol relapse, and the majority of those relapses involved heavy drinking.¹² The factors most strongly associated with relapse included younger age, having previously relapsed, significant psychiatric conditions, continued alcohol use after a cirrhosis diagnosis, shorter abstinence before listing, and prior alcohol treatment enrollment. A larger prospective study using a blood biomarker detected relapse in about a third of patients over a three-year follow-up period.¹³

But relapse is not the same thing as graft failure or death. A single episode of drinking does not automatically destroy a transplanted liver. What matters is the pattern and severity. One large study found that patients with excessive alcohol relapse had five-year survival of about 82% compared to 86% in those without excessive relapse — a gap, but not a dramatic one. The difference widened at ten years, though, to 49% versus 75%.¹⁴ Another study found that alcohol relapse increased the risk of death mainly during the first five years after transplant, but beyond that window, the negative outcomes in alcohol-related liver disease patients were not clearly attributable to recidivism.¹⁵ Long-term survival is affected by relapse, but the overall picture is more nuanced than the assumption that any drinking after transplant means a wasted organ.

Blood Tests That Changed the Monitoring Game

For years, transplant teams relied on patient self-reporting and indirect liver function markers to detect alcohol use after transplant. Neither was reliable. People underreport drinking, and the traditional blood tests used to flag liver injury can be thrown off by the immunosuppressive drugs that every transplant recipient takes. The introduction of phosphatidylethanol, known as PEth, has changed that. PEth is a substance formed in red blood cell membranes only when alcohol is present, and it can detect moderate to heavy drinking over the prior three to four weeks.¹⁶

PEth testing is now being used both before and after transplant. In candidates awaiting transplant, it provides an objective check on whether someone is actually abstinent, giving clinicians harder data than interviews alone.¹⁷ After transplant, routine PEth monitoring can catch relapses that clinical criteria alone might miss. In one prospective study comparing PEth testing against clinical assessment, about 8% of patients tested positive on PEth despite being flagged as non-relapsing by clinical criteria.¹³ Earlier identification means earlier intervention, which is the whole point.

Integrated Addiction Treatment Before and After Surgery

The most promising development in improving outcomes for transplant recipients with alcohol use disorder is the integration of addiction care directly into the transplant program. When addiction specialists, psychologists, and transplant hepatologists work in the same clinic rather than operating as separate referrals, the results improve considerably. One comparison from a transplant center in Rome found that patients who received integrated treatment had a relapse rate of about 16%, compared to roughly 35% in those who received non-integrated care. Mortality was also lower — about 15% versus 38%.¹⁸ The co-location of addiction and transplant services improves communication between providers, reduces the chances that someone falls through the cracks, and makes it easier for patients to access the behavioral therapies they need.¹⁹

Despite this evidence, many transplant centers have not yet built these integrated programs. There are calls in the literature for creating formal “Centers of Excellence” for post-transplant alcohol use disorder care and for advocating policy reforms that ensure insurance coverage for these services.²⁰ The infrastructure is still catching up to the evidence.

Family Support and Mental Health as Predictors

The psychosocial factors that predict relapse extend well beyond the patient’s willpower. Family support is one of the strongest protective factors. Higher levels of perceived family support have been linked to lower risk of post-transplant alcohol relapse, and the protective effect works partly through reducing depression and anxiety symptoms, which are themselves risk factors for drinking.²¹ In a Scandinavian study using PEth-based monitoring, limited social support nearly tripled the risk of relapse, while having a relative involved during the transplant evaluation cut it substantially.²²

That same study found something else worth noting: patients who received an insufficient assessment of their alcohol use disorder before transplant had nearly triple the relapse risk, while those who received a formal diagnosis of alcohol dependence actually had significantly lower relapse rates. Getting a proper diagnosis is not just paperwork — it connects people to appropriate treatment and sets expectations for ongoing care. This underscores a recurring theme in the field: what happens around the transplant matters as much as the transplant itself.

Disparities in Who Gets Listed

Access to liver transplant for alcohol-related disease is not equitable. One of the starkest disparities is between men and women. In one study, women had 36% lower odds of being listed for transplant compared to men after adjusting for other factors. Among those who were listed, women had more than twice the odds of being removed from the waitlist and half the odds of actually receiving a transplant.²³ The reasons are layered. Women are more likely to have co-occurring mood disorders like depression and anxiety, and unemployment — both of which served as indirect barriers to listing. A nationwide French cohort study confirmed the pattern and added that women tend to have lower creatinine levels due to less muscle mass, which can make their disease severity look lower on scoring systems used for organ allocation, even when they are equally sick.²⁴

Beyond gender, there are center-to-center differences in policies, variable access to mental health and addiction services, and systemic barriers related to insurance. A comprehensive review identified rising disease burden, variable transplant practices, underdiagnosis, stigma, and gaps in insurance coverage for necessary addiction services as interacting problems that limit access to transplant for patients who might benefit.²⁰ Where you live, which center evaluates you, and how well-resourced their psychosocial assessment team is can all influence whether you get listed.

The Ethics Debate and Public Perception

The ethical tension around transplanting organs into people with alcohol-related disease has never fully resolved. On one side is the medical evidence: these patients do well after transplant, and denying them access based on the cause of their disease is, in the view of many ethicists, a form of discrimination that is not applied to other self-inflicted conditions. On the other side are real concerns about public perception and organ donation willingness. Surveys have shown that some potential donor families might refuse to donate if they believed the recipient could be someone with an alcohol problem. There is also a fairness question within the allocation system itself: patients with severe alcoholic hepatitis tend to score very high on the severity scales used to prioritize transplant, meaning they can leapfrog other candidates who have been waiting longer.²⁵

The stigma around alcohol use disorder complicates the picture at every level. There remains a perception among some clinicians and the public that alcohol-related liver failure is “self-inflicted” and that patients are morally responsible for their condition in a way that, say, someone with autoimmune liver disease is not. This perception can delay referrals and affect how aggressively a patient’s case is advocated for within a transplant committee.²⁶

Living Donor Transplantation as an Alternative

One way to sidestep the ethical tension of using deceased-donor organs for alcohol-related disease is living-donor liver transplantation. Because the liver can regenerate, a healthy person can donate a portion of their liver and both the donor and recipient will regrow functional organs. This approach has a particular appeal for patients with alcohol-related disease because it does not draw from the deceased-donor pool, removing the zero-sum argument that giving a liver to someone with an alcohol history means taking it from someone else. Living donation may represent an important mechanism for providing early transplant options to patients with alcohol-related disease while eliminating the allocation dilemma around scarce deceased-donor organs.²⁶ In practice, living-donor transplant is still much less common than deceased-donor transplant in Western countries, but it is a growing area of interest for this population.

Cancer Risk After Transplant for Alcohol-Related Disease

A concern that gets less public attention than relapse is the elevated risk of certain cancers after transplant in people whose original disease was alcohol-related. All transplant recipients face increased cancer risk because of the immunosuppressive medications they take for the rest of their lives, but the combination of a prior heavy-drinking history, immunosuppression, and often a smoking history creates a particularly high risk for cancers of the mouth, throat, and lungs.²⁷ This is an area where the transplant team’s follow-up plan matters a great deal. Patients transplanted for alcohol-related liver disease benefit from aggressive cancer screening in the years after surgery, with particular attention to head, neck, and lung cancers. Smoking cessation support is equally critical and is often discussed alongside alcohol abstinence during the evaluation process.

This cancer risk also illustrates why the conversation around transplant for alcohol-related disease is not just about whether someone deserves an organ. It is about building a long-term care plan that addresses every dimension of a patient’s health — from liver function to addiction to oncology screening — and sustaining that plan over decades. The transplant itself is a single event. What determines whether it was worthwhile is the quality of everything that happens afterward.